Till now, there has been no comprehensive meta-analyses comparing the day and night time efficacy and safety features between traditional SAP therapy and the currently used CLC insulin delivery for pediatric and adolescents with type 1 diabetes. The gene discussed is INS; the disease is type 1 diabetes mellitus.